

# Morgan Stanley

## Key Information Document

### Purpose

This document provides you with key information about this product. It is not marketing material. The information is required by the Packaged Retail and Insurance-Based Investment Products Regulation ("PRIIPs") to help you understand the key features, risks, costs and potential gains and losses of this product and to help you compare it with other products covered by PRIIPs.

### Product

Product name	5 Year EUR Phoenix Autocall Certificates linked to Novo Nordisk A, Sanofi SA and UnitedHealth Group Incorporated
Product identifiers	ISIN: DE000MS0H190   Series number: G957   WKN: MS0H19
PRIIP manufacturer	Morgan Stanley & Co. International plc ( <a href="https://sp.morganstanley.com/EU/">https://sp.morganstanley.com/EU/</a> ). The product issuer is Morgan Stanley B.V. with a guarantee by Morgan Stanley.
Telephone number	+44-20-7677-6140
Competent authority of the PRIIP manufacturer	Morgan Stanley & Co. International plc is not established in the European Union (EU) or supervised by an EU competent authority. It is authorised by the U.K. Prudential Regulation Authority and regulated by the U.K. Financial Conduct Authority and U.K. Prudential Regulation Authority.
Date and time of production	15 April 2026 13:44 Rome local time

You are about to purchase a product that is not simple and may be difficult to understand.

### 1. What is this product?

Type	German law governed equity-linked certificates / Return depends on the performance of the underlyings / No capital protection against market risk
Term	The product has a fixed term and will be due on 25 September 2030, subject to an early redemption.
Objectives	<p>The product is designed to provide a return in the form of (1) conditional coupon payments and (2) a cash payment on termination of the product. The timing and amount of these payments will depend on the performance of the <b>underlyings</b>. If, at maturity, the <b>final reference price</b> of the <b>worst performing underlying</b> has fallen below its <b>barrier price</b>, the product may return less than the <b>unit reference amount</b> or even zero.</p> <p><b>Early termination following an autocall:</b> The product will terminate prior to the <b>maturity date</b> if, on any <b>autocall observation date</b>, the <b>reference price</b> of the <b>worst performing underlying</b> is at or above its <b>autocall barrier price</b>. On any such early termination, you will on the immediately following <b>autocall payment date</b> receive, in addition to any final coupon payment, a cash payment equal to the autocall payment of EUR 1,000.00. No coupon payments will be made on any date after such <b>autocall payment date</b>.</p> <p><b>Coupon:</b> If the product has not terminated early, on each <b>coupon payment date</b> you will receive a coupon payment of EUR 18.10 together with any previously unpaid coupon payments if the <b>reference price</b> of the <b>worst performing underlying</b> is at or above its <b>coupon barrier price</b> on the immediately preceding <b>coupon observation date</b>. If this condition is not met, you will receive no coupon payment on such <b>coupon payment date</b>.</p> <p><b>Termination on the maturity date:</b> If the product has not terminated early, on the <b>maturity date</b> you will receive:</p> <ol style="list-style-type: none"><li>if the <b>final reference price</b> of the <b>worst performing underlying</b> is at or above its <b>barrier price</b>, a cash payment equal to EUR 1,000.00; or</li><li>if the <b>final reference price</b> of the <b>worst performing underlying</b> is below its <b>barrier price</b>, a cash payment directly linked to the performance of the <b>worst performing underlying</b>. The cash payment will equal (i) the <b>unit reference amount</b> multiplied by (ii) (A) the <b>final reference price</b> of the <b>worst performing underlying</b> divided by (B) its <b>strike price</b>.</li></ol> <p>Under the product terms, certain dates specified below will be adjusted if the respective date is either not a business day or not a trading day (as applicable). Any adjustments may affect the return, if any, you receive.</p> <p>The product terms also provide that if certain exceptional events occur (1) adjustments may be made to the product and/or (2) the issuer may terminate the product early. These events are specified in the product terms and principally relate to the <b>underlyings</b>, the product and the issuer. The return (if any) you receive on such early termination is likely to be different from the scenarios described above and may be less than the amount you invested.</p> <p>When purchasing this product during its lifetime, the purchase price may include accrued coupon on a pro rata basis.</p> <p>You do not have any entitlement to a dividend from any of the <b>underlyings</b> and you have no right to any further entitlement resulting from any such <b>underlying</b> (e.g., voting rights).</p>

Underlyings	Ordinary shares of Novo Nordisk A/S (NOVOB; ISIN: DK0062498333; Bloomberg: NOVOB DC Equity), Sanofi SA (SAN; ISIN: FR0000120578; Bloomberg: SAN FP Equity) and UnitedHealth Group Inc (UNH; ISIN: US91324P1021; Bloomberg: UNH UN Equity)	Final reference price	The reference price on the final valuation date
Asset class	Equity	Initial valuation date	18 September 2025
Unit reference amount	EUR 1,000.00	Final valuation date	18 September 2030
Product currency	Euro (EUR)	Maturity date / term	25 September 2030
Underlying currencies	• NOVOB: Danish Krone (DKK) • SAN: EUR • UNH: U.S. Dollar (USD)	Autocall observation dates	The 18th calendar day of each March, June, September and December from September 2026 (inclusive) to June 2030 (inclusive)
Issue date	19 September 2025	Autocall barrier price	100.00% of the initial reference price
Initial reference price	The reference price on the initial valuation date	Autocall payment date	The day falling 5 business days after the relevant autocall observation date
Strike price	100.00% of the initial reference price	Coupon observation dates	The 18th calendar day of each March, June, September and December from


			December 2025 (inclusive) to the <b>final valuation date</b> (inclusive)
<b>Barrier price</b>	60.00% of the <b>initial reference price</b>	<b>Coupon barrier price</b>	60.00% of the <b>initial reference price</b>
<b>Reference price</b>	The closing price of an <b>underlying</b> as per the relevant <b>reference source</b>	<b>Coupon payment dates</b>	The day falling 5 <b>business days</b> after the relevant <b>coupon observation date</b> .
<b>Reference sources</b>	<ul style="list-style-type: none"> <li>• NOVOB: Nasdaq Copenhagen A/S</li> <li>• SAN: Euronext - Euronext Paris</li> <li>• UNH: New York Stock Exchange, Inc.</li> </ul>	<b>Worst performing underlying</b>	For a given date, the <b>underlying</b> with the worst performance between the <b>initial reference price</b> and the relevant <b>reference price</b>

**Intended retail investor** The product is intended to be offered to retail investors who fulfil all of the criteria below:

1. they have basic knowledge and/or experience of investing in similar products which provide a similar market exposure and have the ability to understand the product and its possible risks and rewards, either independently or through professional advice;
2. they seek income, expect the movement in the underlyings to perform in a way that generates a positive return. They have a medium investment horizon and understand that the product may terminate early;
3. they are able to bear a total loss of their initial investment, consistent with the redemption profile of the product at maturity (market risk);
4. they accept the risk that the issuer or guarantor could fail to pay or perform its obligations under the product irrespective of the redemption profile of the product (credit risk);
5. they are willing to accept a level of risk of 6 out of 7 to achieve potential returns, which reflects the second highest risk (as shown in the summary risk indicator below which takes into account both market risk and credit risk).

## 2. What are the risks and what could I get in return?

**Risk indicator**



The risk indicator assumes you keep the product until 25 September 2030. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 6 out of 7, which is the second-highest risk class. This rates the potential losses from future performance at a high level, and poor market conditions are very unlikely to impact our capacity to pay you.

Inflation erodes the purchasing value of cash over time and this may result in the decline in real terms of any capital reimbursed or interest you may be paid under the investment.

This product does not include any protection from future market performance so you could lose some or all of your investment.

For detailed information about all risks relating to the product please refer to the risk sections of the prospectus and any supplements thereto as specified in the section "7. Other relevant information" below.

**Performance scenarios** What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The scenarios shown are illustrations based on results from the past and on certain assumptions. Markets could develop very differently in the future.

<b>Recommended holding period:</b>	<b>Until the product is called or matures</b>		
	This may be different in each scenario and is indicated in the table		
<b>Example investment:</b>	EUR 10,000		
<b>Scenarios</b>		<i>If you exit after 1 year</i>	<i>If you exit at call or maturity</i>
<b>Minimum</b>	<b>There is no minimum guaranteed return. You could lose some or all of your investment.</b>		
<b>Stress</b> (product ends after 4 years and 5 months)	<b>What you might get back after costs</b> Average return each year	EUR 343 -96.57%	EUR 418 -51.03%
<b>Unfavourable</b> (product ends after 4 years and 5 months)	<b>What you might get back after costs</b> Average return each year	EUR 4,367 -56.33%	EUR 2,590 -26.20%
<b>Moderate</b> (product ends after 4 years and 5 months)	<b>What you might get back after costs</b> Average return each year	EUR 8,291 -17.09%	EUR 7,291 -6.86%
<b>Favourable</b> (product ends after 4 years and 5 months)	<b>What you might get back after costs</b> Average return each year	EUR 12,520 25.20%	EUR 21,018 18.18%

The favourable, moderate, unfavourable and stress scenarios represent possible outcomes that have been calculated based on simulations using the past performance of the **underlyings** over a period of up to 5 years. In the case of an early redemption, it has been assumed that no reinvestment has occurred. The stress scenario shows what you might get back in extreme market circumstances.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

## 3. What happens if Morgan Stanley B.V. is unable to pay out?

You are exposed to the risk that the issuer or guarantor might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or an official directive for resolution action. This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not covered by any deposit protection scheme.

## 4. What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different investment periods.

The duration of this product is uncertain as it may terminate at different times depending on how the market evolves. The amounts shown here consider two different scenarios (early call and maturity). In case you decide to exit before the product ends, exit costs may apply in addition to the amounts shown here.

We have assumed:

- EUR 10,000 is invested
- a performance of the product that is consistent with each holding period shown.

	<i>If the product is called at the first possible date, on 25 September 2026</i>	<i>If the product reaches maturity</i>
<b>Total costs</b>	EUR 79	EUR 79
<b>Annual cost impact*</b>	1.31%	0.17% each year

\*This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at maturity your average return per year is projected to be -6.68% before costs and -6.85% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

### Composition of costs

	<b>One-off costs upon entry or exit</b>	<b>If you exit after 1 year</b>
<b>Entry costs</b>	0.79% of the amount you pay when entering this investment. These costs are already included in the price you pay.	EUR 79
<b>Exit costs</b>	5.36% of your investment before it is paid out to you. These costs are already included in the price you receive and are only incurred if you exit before maturity. If an early redemption occurs or if you hold the product until maturity, no exit costs will be incurred.	EUR 536
<b>Ongoing costs taken each year</b>		
<b>Management fees and other administrative or operating costs</b>	0.00% of your investment amount per year. This is an estimate of the actual costs.	EUR 0

## 5. How long should I hold it and can I take money out early?

### Recommended holding period: 4 years and 5 months

The product aims to provide you with the return described under "1. What is this product?" above. However, this only applies if the product is held to maturity. It is therefore recommended that the product is held until 25 September 2030 (maturity), although the product may terminate early.

The product does not guarantee the possibility to disinvest other than by selling the product either (1) through the exchange (if the product is exchange traded) or (2) off-exchange, where an offer for such product exists. Save as otherwise disclosed in exit costs (see section "4. What are the costs?" above), no fees or penalties will be charged by the issuer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

<b>Exchange listing</b>	EuroTLX	<b>Price quotation</b>	Units
<b>Smallest tradable unit</b>	1 unit		

In volatile or unusual market conditions, or in the event of technical faults/disruptions, the purchase and/or sale of the product can be temporarily hindered and/or suspended and may not be possible at all.

## 6. How can I complain?

Any complaint regarding the conduct of the person advising on, or selling, the product can be submitted directly to that person.

Any complaint regarding the product or the conduct of the manufacturer of this product can be submitted in writing at the following address: Morgan Stanley & Co. International plc, Structured Products Floor 01, 20 Bank Street, Canary Wharf, London, E14 4AD, by email to: [rspcomplaints@morganstanley.com](mailto:rspcomplaints@morganstanley.com). Please see also <https://sp.morganstanley.com/EU/>. Complaints should include the name of the product, ISIN and reason for the complaint.

## 7. Other relevant information

The information contained in this Key Information Document does not constitute a recommendation to buy or sell the product and is no substitute for individual consultation with your bank or advisor.

The offering of this product has not been registered under the U.S. Securities Act of 1933. This product may not be offered or sold, directly or indirectly, in the United States of America or to U.S. persons. The term "U.S. person" is defined in Regulation S under the U.S. Securities Act of 1933, as amended.

Any additional documentation in relation to the product, in particular, the issuance programme documentation, any supplements thereto and the product terms are published on <https://sp.morganstanley.com/EU/>, all in accordance with relevant legal requirements. These documents are also available free of charge from Morgan Stanley & Co. International plc, Structured Products Floor 01, 20 Bank Street, Canary Wharf, London, E14 4AD.